Antares Pharma (ATRS) PT Raised to $8.00

Antares Pharma (NASDAQ:ATRS) had its price objective boosted by Jefferies Financial Group to $8.00 in a report published on Tuesday, The Fly reports. The firm currently has a buy rating on the specialty pharmaceutical company’s stock. Jefferies Financial Group also issued estimates for Antares Pharma’s FY2018 earnings at ($0.09) EPS, Q1 2019 earnings at ($0.01) EPS, Q2 2019 earnings at $0.00 EPS, Q3 2019 earnings at $0.00 EPS, Q4 2019 earnings at $0.01 EPS, FY2020 earnings at $0.06 EPS and FY2021 earnings at $0.15 EPS.

A number of other equities research analysts have also commented on ATRS. BidaskClub lowered Antares Pharma from a buy rating to a hold rating in a research report on Wednesday, July 11th. ValuEngine lowered Antares Pharma from a buy rating to a hold rating in a research report on Thursday, August 2nd. HC Wainwright set a $4.00 price target on Antares Pharma and gave the stock a buy rating in a research report on Wednesday, August 8th. Finally, Piper Jaffray Companies reiterated a buy rating and issued a $4.00 price objective on shares of Antares Pharma in a research report on Friday, August 17th. One investment analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of Buy and a consensus price target of $5.44.

NASDAQ ATRS traded up $0.03 during trading hours on Tuesday, reaching $3.64. 1,242,204 shares of the company’s stock were exchanged, compared to its average volume of 1,338,286. The firm has a market cap of $557.70 million, a PE ratio of -33.09 and a beta of 0.55. Antares Pharma has a one year low of $1.68 and a one year high of $3.93. The company has a debt-to-equity ratio of 1.03, a current ratio of 2.29 and a quick ratio of 1.89.

Antares Pharma (NASDAQ:ATRS) last released its quarterly earnings results on Tuesday, November 6th. The specialty pharmaceutical company reported ($0.01) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.02) by $0.01. The business had revenue of $17.87 million for the quarter, compared to analyst estimates of $15.13 million. Antares Pharma had a negative return on equity of 59.08% and a negative net margin of 27.84%. As a group, equities analysts expect that Antares Pharma will post -0.11 earnings per share for the current year.

In other Antares Pharma news, CEO Robert F. Apple sold 43,000 shares of the stock in a transaction on Tuesday, August 21st. The stock was sold at an average price of $3.75, for a total value of $161,250.00. Following the transaction, the chief executive officer now directly owns 1,573,562 shares in the company, valued at approximately $5,900,857.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jacques Gonella sold 400,000 shares of the stock in a transaction on Tuesday, October 2nd. The shares were sold at an average price of $3.79, for a total value of $1,516,000.00. Following the completion of the transaction, the director now owns 9,585,848 shares in the company, valued at $36,330,363.92. The disclosure for this sale can be found here. Insiders sold a total of 492,507 shares of company stock worth $1,830,227 over the last quarter. Corporate insiders own 12.20% of the company’s stock.

Several large investors have recently bought and sold shares of ATRS. Metropolitan Life Insurance Co. NY boosted its position in shares of Antares Pharma by 127.0% in the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 51,612 shares of the specialty pharmaceutical company’s stock worth $133,000 after purchasing an additional 28,875 shares during the last quarter. MML Investors Services LLC boosted its position in shares of Antares Pharma by 92.4% in the 3rd quarter. MML Investors Services LLC now owns 40,600 shares of the specialty pharmaceutical company’s stock worth $136,000 after purchasing an additional 19,500 shares during the last quarter. JPMorgan Chase & Co. boosted its position in shares of Antares Pharma by 533.6% in the 1st quarter. JPMorgan Chase & Co. now owns 448,634 shares of the specialty pharmaceutical company’s stock worth $987,000 after purchasing an additional 377,824 shares during the last quarter. Perkins Capital Management Inc. raised its stake in Antares Pharma by 37.0% during the 3rd quarter. Perkins Capital Management Inc. now owns 435,000 shares of the specialty pharmaceutical company’s stock worth $1,462,000 after buying an additional 117,500 shares during the period. Finally, Schwab Charles Investment Management Inc. raised its stake in Antares Pharma by 4.6% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 744,188 shares of the specialty pharmaceutical company’s stock worth $1,921,000 after buying an additional 32,626 shares during the period. Institutional investors and hedge funds own 38.62% of the company’s stock.

About Antares Pharma

Antares Pharma, Inc, a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; and Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.

See Also: What is the balance sheet?

The Fly

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply